Navigation Links
Kosan Biosciences to Host Research & Development Day on October 31, 2007
Date:10/25/2007

on the "Events Calendar" tab under the same heading, "Investors/Press." A replay of the presentation will be available for 30 days following event. Please connect to Kosan's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical

trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at ht
'/>"/>

SOURCE Kosan Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Decision Resources Group finds that the majority ... the United States believe that ... be the level of savings achievable by their ... cost to patients. Payers plan to leverage preferential ... expectations in order to encourage physician prescribing of ...
(Date:7/30/2014)... July 30, 2014  The Chicago Bears are excited ... of Dermatology (Academy) in an effort to raise awareness ... will host free SPOT me™ skin cancer screenings at ... Soldier Field. SPOT me™ is an educational campaign ... dangers and risks of skin cancer, and encourages people ...
(Date:7/30/2014)... While administrative claims and other data ... a relatively long period of time, there has ... of these ‘big data’ for comparisons of interventions ... powerful computer technology with the plethora of data ... significant promise for identifying optimal interventions for specific ...
(Date:7/30/2014)... 30, 2014 Sales Horizons, a leader ... blended sales training programs for companies engaged in complex ... used by thousands of salespeople over 25 years in ... program can be customized to address the unique sales ... blended sales training program consists of two parts: ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3
... SAN FRANCISCO, Nov. 12 VIA Pharmaceuticals,(Nasdaq: ... on the development of,compounds for the treatment ... its clinical advisory board. Joining the clinical ... Professor of Medicine,Harvard Medical School, and Senior ...
... Associated with Chronic Pain Conditions in Patients Who ... ... FRAZER, Pa., Nov. 12 Cephalon, Inc. (Nasdaq:,CEPH) today announced ... Food and Drug Administration (FDA) seeking approval to,market FENTORA(R) (fentanyl buccal ...
... N.J. -- The Edwin A. Stevens Society of Stevens Institute ... School of Systems and Enterprises, Dr. Dinesh Verma, with the ... at the Park Avenue Club in Florham Park, N.J., Nov. ... is by invitation only., The Presidents Leadership Award is presented ...
Cached Biology Technology:VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 2VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 3VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 4Cephalon Submits Supplemental New Drug Application for FENTORA 2Cephalon Submits Supplemental New Drug Application for FENTORA 3Cephalon Submits Supplemental New Drug Application for FENTORA 4Cephalon Submits Supplemental New Drug Application for FENTORA 5Cephalon Submits Supplemental New Drug Application for FENTORA 6Cephalon Submits Supplemental New Drug Application for FENTORA 7Dr. Dinesh Verma to be honored with President's Leadership Award at Edwin A. Stevens Society Gala 2Dr. Dinesh Verma to be honored with President's Leadership Award at Edwin A. Stevens Society Gala 3
(Date:7/30/2014)... iodine-125 (125I) in cancer treatment has been shown ... are critical for neural transmission between the peripheral ... colleagues from Institute of Radiation Medicine, Chinese Academy ... be implanted into rat dorsal root ganglia (DRG) ... with different radioactivity (0, 14.8, 29.6 MBq) were ...
(Date:7/30/2014)... first high-resolution map of the carbon stocks stored ... The new and improved methodology used to make ... market-based carbon economies. The new carbon map ... it provides the critical input to studies of ... and enforcement purposes. The technique includes the determination ...
(Date:7/29/2014)... researchers sometimes need to get back to basics. ... to study the impacts of the bumphead parrotfish ... at two remote locations in the central Pacific ... computer simulation, McCauley, an assistant professor in the ... his colleagues sought to understand whether the world,s ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Underwater elephants 2Underwater elephants 3
... University of Illinois scientists have learned that a specific ... health. "In experiments with mice, we knocked out ... body to make arachidonic acid. Without arachidonic acid, the ... itchy, they scratched themselves continuously, and they developed a ...
... A team of researchers from the United States and Europe ... a role in the etiology of common forms of kidney ... variations in DNA sequences in more than 65,000 individuals of ... be more frequent among people with poor kidney function or ...
... Just one "pulse" of artificial light at night disrupts ... by Dr. Rachel Ben-Shlomo of the University of Haifa-Oranim ... Charalambos P. Kyriacou of the University of Leicester. "Damage ... is therefore important to understand the causes of this ...
Cached Biology News:U of I study: Lack of omega-6 fatty acid linked to severe dermatitis 2International research team discovers novel genes influencing kidney disease risk 2